Category Archives: Deals

Putting the M Back in M&A

By Jennifer Ringler | Published: December 13, 2011
Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from relying [...]
Also posted in Agency Insight, Biotech, FDA | Tagged , , , | Leave a comment

Generics Win in an Express Scripts/Medco deal

By Ben Comer | Published: July 27, 2011
As a preferred generics supplier to Medco’s mail-order business, Novartis’ Sandoz division, for one, should be waiting with bated breath – and champagne at the ready – for an FTC approval of Express Scripts’ proposed $29.1 billion acquisition of Medco, which would combine two of the three largest pharmacy benefits managers (PBM), according to industry [...]
Also posted in Strategy, pricing | Tagged , , , , , , | 4 Comments

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

By Ben Comer | Published: May 4, 2011
If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the world’s [...]
Also posted in Strategy | Tagged , , , , | 3 Comments

AstraZeneca Signs Exclusive Distribution Deal for Vandetanib

By Ben Comer | Published: April 27, 2011
As the number of drugs targeting small populations increases, managing numerous drug distribution channels and educating the relevant parties – specialty pharmacists, payers, physicians, and patients – becomes a daunting task. Specialty pharmacies that handle seven to 10 major disease states, after all, might only see three or four patients with a given rare disease, [...]
Also posted in FDA, Legal, Market Access, Regulatory, Strategy, healthcare, pricing | Tagged , , , | Leave a comment

First Chinese Product Development Partnership Targets Tuberculosis, Malaria, AIDS

By Ben Comer | Published: March 24, 2011
A Chinese scientific foundation and a not-for-profit tuberculosis organization announced a partnership aimed at developing new medicines for underserved public health diseases. Billed as the first Chinese product development partnership (PDP), the Global Health R&D Center of China (GHRC) hopes to discover and develop new treatments for tuberculosis (TB) and other diseases by collaborating with pharmaceutical [...]
Also posted in Biotech, Corporate Responsibility, Emerging Markets, Global, IP, Market Access, R&D, Technology, patient compliance | Tagged , | Leave a comment